Ligand validation:8IY1

3AM: [(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] dihydrogen phosphate

3AM is a Ligand Of Interest in 8IY1 designated by the Author

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
8IY1_3AM_C_101	86%	41%	0.103	0.98	1.02	1.33	1	2	0	0	96%	0.3252
8IY1_3AM_C_102	86%	41%	0.104	0.98	1.05	1.29	1	2	0	0	96%	0.3252
8IY1_3AM_F_101	80%	41%	0.111	0.969	0.98	1.37	1	3	0	0	96%	0.3443
8IY1_3AM_E_101	79%	40%	0.12	0.974	1.01	1.39	1	3	0	0	96%	0.3348
8IY1_3AM_D_101	79%	38%	0.114	0.967	1.01	1.47	1	2	0	0	96%	0.3157
8IY1_3AM_B_101	77%	24%	0.114	0.962	1.07	2.15	2	7	2	0	96%	0.3348
8IY1_3AM_D_102	77%	40%	0.113	0.961	1.06	1.31	1	2	0	0	96%	0.3157
8IY1_3AM_E_102	76%	39%	0.125	0.969	1.07	1.39	1	3	0	0	96%	0.3348
8IY1_3AM_B_102	75%	39%	0.118	0.961	1.02	1.41	1	2	0	0	96%	0.3348
8IY1_3AM_F_102	75%	40%	0.126	0.968	1.03	1.36	1	3	0	0	96%	0.3443
8IY1_3AM_A_102	72%	37%	0.129	0.961	1.05	1.47	1	3	0	0	96%	0.3252
8IY1_3AM_A_101	70%	23%	0.136	0.963	1.27	2.05	2	6	1	0	96%	0.3252
8IY0_3AM_C_101	79%	37%	0.126	0.981	1.1	1.46	1	4	0	0	96%	0.3157
8IY2_3AM_C_204	57%	58%	0.174	0.959	0.69	0.89	-	1	0	0	96%	0.3157
3IT3_3AM_B_343	94%	12%	0.074	0.972	2.61	1.65	7	3	0	0	100%	1
3AGN_3AM_A_115	92%	45%	0.095	0.987	0.96	1.17	1	2	0	0	100%	0.9783
3AGO_3AM_A_115	73%	23%	0.139	0.968	1.45	1.85	3	7	0	0	100%	0.9783
3C0I_3AM_A_338	70%	5%	0.118	0.936	3.12	2.49	4	4	0	0	100%	1

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM133198.